Phase 1 Myelodysplastic Syndrome Clinical Trials
109 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 109 trials
Recruiting
Phase 1Phase 2
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled24 locationsNCT05320198
Recruiting
Phase 1Phase 2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
National Cancer Institute (NCI)160 enrolled1 locationNCT06303193
Recruiting
Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.27 enrolled22 locationsNCT04953910
Recruiting
Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.18 enrolled21 locationsNCT04953897
Recruiting
Phase 1
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center33 enrolled1 locationNCT06195891
Recruiting
Phase 1
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+6 more
National Cancer Institute (NCI)54 enrolled21 locationsNCT06484062
Recruiting
Phase 1Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Phase 1Phase 2
A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeiGene260 enrolled46 locationsNCT04771130
Recruiting
Phase 1Phase 2
Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes
Myelodysplastic Syndromes
West Virginia University26 enrolled1 locationNCT06923488
Recruiting
Phase 1
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Recurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Myelodysplastic SyndromeRecurrent Juvenile Myelomonocytic Leukemia+3 more
Children's Oncology Group36 enrolled19 locationsNCT06247787
Recruiting
Phase 1Phase 2
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Myelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center58 enrolled1 locationNCT04493138
Recruiting
Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center38 enrolled1 locationNCT03896269
Recruiting
Phase 1Phase 2
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Recurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeRefractory Acute Lymphoblastic Leukemia+3 more
M.D. Anderson Cancer Center120 enrolled1 locationNCT02392572
Recruiting
Phase 1Phase 2
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
Proton TherapyAcute Myeloid Leukemia (AML)Myelodysplastic Neoplasm+2 more
Institute of Hematology and Blood Transfusion, Czech Republic16 enrolled2 locationsNCT07532824
Recruiting
Phase 1Phase 2
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Chordia Therapeutics, Inc.225 enrolled8 locationsNCT05732103
Recruiting
Phase 1
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
Recurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+4 more
National Cancer Institute (NCI)42 enrolled5 locationsNCT03816319
Recruiting
Phase 1
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
AMLMyelodysplastic SyndromesCML+3 more
University of Alabama at Birmingham50 enrolled1 locationNCT06047886
Recruiting
Phase 1
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.266 enrolled18 locationsNCT06656494
Recruiting
Phase 1
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Acute Myeloid LeukemiaMyelodysplastic Syndromes
GluBio Therapeutics Inc.48 enrolled8 locationsNCT06146257
Recruiting
Phase 1
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Acute Myeloid LeukemiaR/R AMLR/R HR-MDS+1 more
Genmab78 enrolled5 locationsNCT07384715